1. Weak Agonistic LPS Restores Intestinal Immune Homeostasis.
- Author
-
Steimle A, Michaelis L, Di Lorenzo F, Kliem T, Münzner T, Maerz JK, Schäfer A, Lange A, Parusel R, Gronbach K, Fuchs K, Silipo A, Öz HH, Pichler BJ, Autenrieth IB, Molinaro A, and Frick JS
- Subjects
- Animals, Biomarkers, CD11c Antigen metabolism, Colitis etiology, Colitis metabolism, Colitis pathology, Disease Models, Animal, Gastrointestinal Microbiome immunology, Homeostasis drug effects, Humans, Inflammatory Bowel Diseases diagnostic imaging, Inflammatory Bowel Diseases etiology, Inflammatory Bowel Diseases metabolism, Inflammatory Bowel Diseases pathology, Intestinal Mucosa drug effects, Lipid A immunology, Lipopolysaccharides pharmacology, Mice, Mice, Knockout, Positron-Emission Tomography, Homeostasis immunology, Immunity, Mucosal, Intestinal Mucosa immunology, Intestinal Mucosa metabolism, Lipopolysaccharides immunology
- Abstract
Generated by gram-negative bacteria, lipopolysaccharides (LPSs) are one of the most abundant and potent immunomodulatory substances present in the intestinal lumen. Interaction of agonistic LPS with the host myeloid-differentiation-2/Toll-like receptor 4 (MD-2/TLR4) receptor complex results in nuclear factor κB (NF-κB) activation, followed by the robust induction of pro-inflammatory immune responses. Here we have isolated LPS from a common gut commensal, Bacteroides vulgatus mpk (BVMPK), which provides only weak agonistic activity. This weak agonistic activity leads to the amelioration of inflammatory immune responses in a mouse model for experimental colitis, and it was in sharp contrast to strong agonists and antagonists. In this context, the administration of BVMPK LPS into mice with severe intestinal inflammation re-established intestinal immune homeostasis within only 2 weeks, resulting in the clearance of all symptoms of inflammation. These inflammation-reducing properties of weak agonistic LPS are grounded in the induction of a special type of endotoxin tolerance via the MD-2/TLR4 receptor complex axis in intestinal lamina propria CD11c
+ cells. Thus, weak agonistic LPS represents a promising agent to treat diseases involving pathological overactivation of the intestinal immune system, e.g., in inflammatory bowel diseases., (Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF